EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY 4.0

A Prospective Observational Study of Anamorelin During Chemoimmunotherapy in Non‐Small Cell Lung Cancer With Cachexia (SPIRAL‐ANA)

Kenji Morimoto iD, Junji Uchino, Makoto Hibino, Yuki Takeyasu, Ken Yamamoto, Yoshie Morimoto, Yusuke Chihara, Takayuki Nakano, Hiroyasu Kaneda, Shunya Tanaka, Shinsuke Ogusu, Yasuhiro Goto und 10 weitere

Journal of Cachexia, Sarcopenia and Muscle · 2026

DOI: 10.1002/jcsm.70340 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, 2026. Verfasst von Kenji Morimoto und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan. Hauptthemen laut MEDLINE: Cachexia, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Hydrazines. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ono Pharmaceutical Co. Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The prognosis of patients with advanced non‐small cell lung cancer (NSCLC) complicated by cancer cachexia remains poor. Anamorelin, a ghrelin receptor agonist, has been approved only in Japan for the treatment of cancer cachexia.

Methods

This prospective multicentre observational study was conducted to evaluate the impact of anamorelin administration on the efficacy and safety of chemoimmunotherapy in patients with NSCLC and cancer cachexia. The primary endpoint was progression‐free survival (PFS), evaluated against a predefined threshold derived from a previous retrospective cohort of patients with cachectic NSCLC treated with chemoimmunotherapy alone. This study was registered in the Japan Registry of Clinical Trials (jRCT1071210053).

Results

Between August 2021 and January 2024, 123 patients were enrolled from 29 institutions in Japan, with 114 included in the full analysis set. The median age was 73 years; 28 (24.6%) were female and 20 patients (17.5%) had a performance status of 2. The objective response rate was 57.9% (95% confidence interval [CI]: 48.7%–66.6%). Median PFS and overall survival (OS) were 6.2 months (95% CI: 4.6–7.7) and 18.5 months (95% CI: 13.1–28.6), respectively. The lower limit of the 95% CI for PFS did not exceed the predefined threshold of 5 months. At week 12, 61 of 85 patients (71.8%) had transitioned from cancer cachexia to a non‐cachectic state. Landmark survival analyses at week 12 showed that patients who achieved this transition had significantly longer OS compared with those who remained cachectic (19.9 vs. 7.1 months; hazard ratio for cachexia vs. transition, 2.19; 95% CI: 1.19–4.02; p = 0.0098). Grade ≥ 3 hyperglycemia was observed in six patients (5.1%), but no new safety signals were identified.

Conclusions

Anamorelin combined with chemoimmunotherapy did not prolong PFS in advanced NSCLC with cancer cachexia, but achieved a high rate of cachexia reversal. Transition to a non‐cachectic state was associated with improved OS, suggesting that cachexia reversal may serve as a surrogate for survival benefit. Trial Registration jRCT1071210053 (jRCT).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CachexiaCarcinoma, Non-Small-Cell LungLung NeoplasmsHydrazinesOligopeptidesImmunotherapyHumansFemaleMaleProspective StudiesAgedMiddle AgedAged, 80 and overTreatment Outcome

Stichwörter der Autor:innen

anamorelincancer cachexiachemoimmunotherapynon‐small cell lung cancer

Substanzen

anamorelinHydrazinesOligopeptides

Autor:innen und Institutionen

  • Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Department of Respiratory Medicine, Shonan Oiso Hospital, Kanagawa, Japan.
  • Department of Respiratory Medicine, Shonan Fujisawa Tokushukai Hospital, Kanagawa, Japan.
  • Department of Thoracic Oncology, Kansai Medical University, Osaka, Japan.
  • Division of Thoracic Oncology, Kobe Minimally Invasive Cancer Center, Hyogo, Japan.
  • Department of Pulmonary Medicine, Kyoto Kuramaguchi Medical Center, Kyoto, Japan.

ORCID-Profile: Kenji Morimoto, Koichi Takayama

Förderung

  • Ono Pharmaceutical Co. Ltd

Zitieren

APA

Morimoto, K., Uchino, J., Hibino, M., Takeyasu, Y., Yamamoto, K., Morimoto, Y., Chihara, Y., Nakano, T., Kaneda, H., Tanaka, S., Ogusu, S., Goto, Y., Nomizo, T., Ota, T., Tsukamoto, H., Takemura, Y., Nakatomi, K., Koba, H., Yoshimine, K., …, & Takayama, K. (2026). A Prospective Observational Study of Anamorelin During Chemoimmunotherapy in Non‐Small Cell Lung Cancer With Cachexia (SPIRAL‐ANA). Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.70340

Vancouver

Morimoto K, Uchino J, Hibino M, Takeyasu Y, Yamamoto K, Morimoto Y, et al. A Prospective Observational Study of Anamorelin During Chemoimmunotherapy in Non‐Small Cell Lung Cancer With Cachexia (SPIRAL‐ANA). Journal of Cachexia, Sarcopenia and Muscle. 2026. doi:10.1002/jcsm.70340

BibTeX
@article{Morimoto2026,
  author = {Morimoto, Kenji and Uchino, Junji and Hibino, Makoto and Takeyasu, Yuki and Yamamoto, Ken and Morimoto, Yoshie and Chihara, Yusuke and Nakano, Takayuki and Kaneda, Hiroyasu and Tanaka, Shunya and Ogusu, Shinsuke and Goto, Yasuhiro and Nomizo, Takashi and Ota, Takayo and Tsukamoto, Hiroaki and Takemura, Yoshizumi and Nakatomi, Katsumi and Koba, Hayato and Yoshimine, Kohei and Shimose, Takayuki and Yamada, Tadaaki and Takayama, Koichi},
  title = {A Prospective Observational Study of Anamorelin During Chemoimmunotherapy in Non‐Small Cell Lung Cancer With Cachexia (SPIRAL‐ANA)},
  journal = {Journal of Cachexia, Sarcopenia and Muscle},
  year = {2026},
  doi = {10.1002/jcsm.70340}
}
Kostenlos starten →